BridgeBio Pharma has been granted a patent for improved processes in preparing compound AG-10, along with pharmaceutically acceptable salts and crystalline forms. The patent includes a method for treating TTR amyloid disease by administering Crystalline Form Type A of Formula IX as its HCl salt. GlobalData’s report on BridgeBio Pharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Premium Insights BridgeBio Pharma Inc - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on BridgeBio Pharma, was a key innovation area identified from patents. BridgeBio Pharma's grant share as of February 2024 was 15%. Grant share is based on the ratio of number of grants to total number of patents.

Treatment of transthyretin amyloid disease using crystalline form type a

Source: United States Patent and Trademark Office (USPTO). Credit: BridgeBio Pharma Inc

A recently granted patent (Publication Number: US11919865B2) discloses a method for treating transthyretin (TTR) amyloid diseases by administering Crystalline Form Type A of Formula IX as its HCl salt to patients in need. This specific form of the compound is characterized by unique X-ray powder diffraction patterns and thermal properties, making it distinct from other crystalline or amorphous forms of Formula IX. The method involves administering the compound with specific weight loss and water uptake characteristics, as well as a differential scanning calorimetry thermogram showing distinct endothermic peaks.

The patent claims cover the treatment of TTR amyloid diseases such as TTR amyloid cardiomyopathy and TTR amyloid polyneuropathy using the specified Crystalline Form Type A of Formula IX as its HCl salt. The method outlined in the patent involves precise measurements and characteristics of the compound to ensure its effectiveness in treating these specific diseases. By focusing on the unique properties of this crystalline form, the patent aims to provide a targeted and efficient treatment option for patients suffering from TTR amyloid diseases, potentially offering a new avenue for managing these conditions.

To know more about GlobalData’s detailed insights on BridgeBio Pharma, buy the report here.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies